NikolaiAlexandrovichPodoltsevMD

Oncology • New Haven, CT

Hematologic Oncology

Assistant Professor, Comprehensive Cancer Center, Yale University School of Medicine

Join to view full profile

Dr. Podoltsev is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Podoltsev's full profile

Already have an account?

Office
333 Cedar St
Yale University School of Medicine Hematology Division
New Haven, CT 06510
Phone+1 203-200-4363

Fax+1 203-785-3788

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
Yale-New Haven Medical CenterResidency, Internal Medicine, 1997 - 2001
St Petersburg Medical State AcademyClass of 1993

Certifications & Licensure

CT State Medical License 2000 - 2025
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Start of enrollment: 2012 Dec 13
Completed
Phase 3
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML Start of enrollment: 2018 Aug 15
Recruiting
Phase 3
Roles: Contact
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2019 Mar 11
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Aplastic anemia in association with multiple myeloma: clinical and pathophysiological insights.
Tinatin Muradashvili, Yuxin Liu, Jennifer VanOudenhove, Sean X Gu, Diane S Krause
Leukemia & Lymphoma. 2024-12-01
Cost-effectiveness of Enasidenib versus conventional care for older patients withmutant refractory/relapsed AML.
Abdulrahman Alhajahjeh, Kishan K Patel, Rory M Shallis, Nikolai A Podoltsev, Tariq Kewan
Leukemia & Lymphoma. 2024-11-19
Global Disparities in the Characteristics and Outcomes of Leukemia Clinical Trials: A Cross-Sectional Study of the ClinicalTrials.gov Database.
Abdulrahman Alhajahjeh, Lara K Rotter, Jessica M Stempel, Alyssa A Grimshaw, Jan Philipp Bewersdorf
JCO Global Oncology. 2024-11-01

Abstracts/Posters

Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience
Nikolai A. Podoltsev, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis
Nikolai A. Podoltsev, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Populati...
Nikolai A. Podoltsev, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab Ozogamicin
Nikolai A. Podoltsev, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Populatio...
Nikolai A. Podoltsev, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United State...
Nikolai A. Podoltsev, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neopl...
Nikolai A. Podoltsev, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best...
Nikolai A. Podoltsev, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Blinatumomab
Nikolai A. Podoltsev, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The VITAL Trial: Phase II Trial of Vosaroxin and Infusional Cytarabine for Frontline Treatment of acute Myeloid LeukemiaClinically Relevant Abstract
Nikolai A. Podoltsev, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center Database
Nikolai A. Podoltsev, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and ...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediat...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Molecular Monitoring Deficient in Older Adults with CMLMay 2nd, 2023
Experts in TrainingJanuary 20th, 2021
Phlebotomy and Hydroxyurea Are Underused in Patients with Polycythemia VeraDecember 1st, 2018
Join now to see all